AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36275049 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 75
Study 36275655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Env Mosaic immunogens combined with a liposomal toll-like receptor-4 adjuvant; monophosphoryl lipid A
Number of subjects: 11
Study 36275655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Env Mosaic immunogens combined with adjuvant
Number of subjects: 11
Study 36275655 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV immunogens
Number of subjects: 11
Study 36275655 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated experimental HIV immunization
Number of subjects: 11
Study 36275715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy combined with Bruton's tyrosine kinase inhibitor and PD-1 antibody.
Number of subjects: 1
Study 36275715 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy.
Number of subjects: 1
Study 36275912 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986012 + nivolumab
Number of subjects: 106
Study 36275912 — intervention group
Group type: COMPARATOR
Intervention: BMS-986012 monotherapy
Number of subjects: 106
Study 36275941 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTaware virtual program
Number of subjects: 7
Study 36275941 — intervention group
Group type: COMPARATOR
Intervention: In-person SCT education
Number of subjects: 7
Study 36276500 — intervention group
Group type: EXPERIMENTAL
Intervention: SIX1 upregulation in HCV-positive female patients with HCC
Number of subjects: 78
Study 36276500 — intervention group
Group type: EXPERIMENTAL
Intervention: SIX1 upregulation
Number of subjects: 78
Study 36276877 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination intent
Number of subjects: 117
Study 36276877 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination acceptability
Number of subjects: 117
Study 36276877 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in vaccine intent
Number of subjects: 117
Study 36276877 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine acceptability related to mental health
Number of subjects: 117
Study 36277312 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised SPC surveillance
Number of subjects: 204233
Study 36277312 — intervention group
Group type: COMPARATOR
Intervention: Traditional SSI surveillance
Number of subjects: 204233
Study 36277481 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 24
Study 36277481 — intervention group
Group type: COMPARATOR
Intervention: Ritlecitinib
Number of subjects: 24
Study 36277662 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment group
Number of subjects: 0
Study 36277662 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0
Study 36277757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual pathway inhibition (DPI) by combining acetylsalicylic acid (ASA) with low-dose rivaroxaban for 12 weeks.
Number of subjects: 159
Study 36277757 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) monotherapy for a 4-weeks run-in period.
Number of subjects: 159
Study 36277775 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG risk score (eRiS)
Number of subjects: 5864
Study 36277775 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG features in conjunction with CAC
Number of subjects: 5864
Study 36277907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Number of subjects: 433
Study 36277907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study 36277907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg (open-label period)
Number of subjects: 433
Study 36277907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open-label period)
Number of subjects: 433
Study 36278119 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation programme via video conference with a specialist Multidisciplinary Team (MDT) for comprehensive remote assessments and virtual individualised interventions.
Number of subjects: 97
Study 36278141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 0
Study 36278141 — intervention group
Group type: COMPARATOR
Intervention: Loving-kindness Meditation (LKM)
Number of subjects: 0
Study 36278141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 36278190 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem therapy
Number of subjects: 0
Study 36278416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP target 110-<130 mm Hg)
Number of subjects: 5369
Study 36278416 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment group (SBP target 130-<150 mm Hg)
Number of subjects: 5369
Study 36278416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 5369
Study 36278416 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment group
Number of subjects: 5369
Study 36278454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study 36278845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional endometrial injury
Number of subjects: 3703
Study 36278845 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injury in early follicular phase (EFP)
Number of subjects: 3703
Study 36278845 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injury in late follicular phase (LFP)
Number of subjects: 3703
Study 36279023 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer
Number of subjects: 1123
Study 36279023 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-negative breast cancer
Number of subjects: 1123
Study 36279023 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer with aromatase inhibitors
Number of subjects: 1123
Study 36279023 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutations in SHR-positive HER2-negative breast cancer with tamoxifen
Number of subjects: 1123
Study 36279162 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention modules for foster caregivers
Number of subjects: 181
Study 36279162 — intervention group
Group type: EXPERIMENTAL
Intervention: General parenting information (e.g., parental self-care, emotion regulation management)
Number of subjects: 181
Study 36279178 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4-stimulated whole blood
Number of subjects: 135
Study 36279414 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 0
Study 36279414 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 0
Study 36279618 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (75, 100, and 125 mg PO daily on days 1 to 21 of a 28-day cycle) in combination with avelumab (10 mg/kg IV every 2 weeks) and cetuximab (400 mg/m)
Number of subjects: 0
Study 36279618 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg) in combination with avelumab and cetuximab
Number of subjects: 0
Study 36279618 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib, avelumab, and cetuximab combination
Number of subjects: 0
Study 36279715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetramer-mediated stimulation of CD8+ T cells
Number of subjects: 0
Study 36279715 — intervention group
Group type: COMPARATOR
Intervention: Tetramer-sorted CD8+ T cells
Number of subjects: 0
Study 36279715 — intervention group
Group type: EXPERIMENTAL
Intervention: ASR gene signature from tetramer-stimulated pp65-specific CD8+ T cells
Number of subjects: 0
Study 36279715 — intervention group
Group type: EXPERIMENTAL
Intervention: ASR gene signature
Number of subjects: 0
Study 36279879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD chemotherapy followed by blinatumomab consolidation (up to 28 μg/day for 28 days, given every 42 days)
Number of subjects: 38
Study 36279879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper-CVAD chemotherapy followed by blinatumomab consolidation
Number of subjects: 38
Study 36279923 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic remission
Number of subjects: 181
Study 36279923 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic remission
Number of subjects: 181
Study 36279923 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier healing on endomicroscopy
Number of subjects: 181
Study 36279923 — intervention group
Group type: COMPARATOR
Intervention: Endoscopically active disease
Number of subjects: 181
Study 36279923 — intervention group
Group type: COMPARATOR
Intervention: Histologic activity
Number of subjects: 181
Study 36280451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 36280451 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 36280461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided central venous catheterisation
Number of subjects: 8586
Study 36280527 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 438
Study 36280578 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave Therapy and Platelet-rich Plasma
Number of subjects: 0
Study 36280578 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled
Number of subjects: 0
Study 36280861 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin plus evolocumab (dual therapy)
Number of subjects: 7556
Study 36280861 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin plus ezetimibe (triple therapy)
Number of subjects: 7556
Study 36280861 — intervention group
Group type: COMPARATOR
Intervention: PCSK9 inhibitor therapy
Number of subjects: 7556
Study 36280861 — intervention group
Group type: COMPARATOR
Intervention: Statin
Number of subjects: 7556
Study 36280861 — intervention group
Group type: COMPARATOR
Intervention: Statin plus ezetimibe
Number of subjects: 7556
Study 36280870 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1701 at 30 mg/kg every 3 weeks
Number of subjects: 171
Study 36280870 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1701
Number of subjects: 171
Study 36281165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at an end-tidal concentration of 1.76 ± 0.15%
Number of subjects: 21
Study 36281165 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted EC50 of sevoflurane
Number of subjects: 21
Study 36281165 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal sevoflurane concentration for successful botulinum toxin injection
Number of subjects: 21
Study 36281192 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glycemia monitoring using Dexcom G5 device before and after surgery (14 days prior and 14 days post-surgery)
Number of subjects: 0
Study 36281192 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard total knee arthroplasty or total hip arthroplasty procedures
Number of subjects: 0
Study 36281192 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of glycemia levels in patients with normal glycemia metabolism
Number of subjects: 0
Study 36281192 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of perioperative glycemic levels
Number of subjects: 0
Study 36281310 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bupivacaine/tramadol
Number of subjects: 100
Study 36281310 — intervention group
Group type: COMPARATOR
Intervention: Late bupivacaine/tramadol
Number of subjects: 100
Study 36281310 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bupivacaine/dexmedetomidine
Number of subjects: 100
Study 36281310 — intervention group
Group type: COMPARATOR
Intervention: Late bupivacaine/dexmedetomidine
Number of subjects: 100
Study 36281983 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive CAD
Number of subjects: 959
Study 36281983 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 959
Study 36282128 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36282526 — intervention group
Group type: EXPERIMENTAL
Intervention: altASDAS
Number of subjects: 958
Study 36282533 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of HPV vaccine during PCP visit
Number of subjects: 86
Study 36282533 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine vaccination at age 9-10
Number of subjects: 86
Study 36282618 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding only support
Number of subjects: 98816
Study 36282618 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding plus support
Number of subjects: 98816
Study 36282798 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0
Study 36282798 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 0
Study 36282798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-related health burden
Number of subjects: 0
Study 36282800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Number of subjects: 1434
Study 36282833 — intervention group
Group type: EXPERIMENTAL
Intervention: spesolimab
Number of subjects: 53
Study 36282833 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study 36283748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 60
Study 36283748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light therapy
Number of subjects: 60
Study 36283748 — intervention group
Group type: COMPARATOR
Intervention: Usual care treatment
Number of subjects: 60
Study 36283748 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual delivery of personalised interventions
Number of subjects: 60
Study 36283759 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic occupational exposures (asbestos, organic solvents)
Number of subjects: 100
Study 36283759 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational toxic substance exposure
Number of subjects: 100
Study 36283759 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA2R1 epitope spreading
Number of subjects: 100
Study 36283927 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 109
Study 36283927 — intervention group
Group type: COMPARATOR
Intervention: Conventional Wound Care (CWC)
Number of subjects: 109
Study 36284205 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 6 months
Number of subjects: 24
Study 36284205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 24
Study 36284205 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group: patients without OSA)
Number of subjects: 24
Study 36284220 — intervention group
Group type: COMPARATOR
Intervention: pegcetacoplan (monthly)
Number of subjects: 0
Study 36284220 — intervention group
Group type: COMPARATOR
Intervention: pegcetacoplan (every other month)
Number of subjects: 0
Study 36284220 — intervention group
Group type: COMPARATOR
Intervention: pegcetacoplan
Number of subjects: 0
Study 36284281 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 221
Study 36284281 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 221
Study 36284281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 36284360 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 60
Study 36284360 — intervention group
Group type: COMPARATOR
Intervention: No Steroids (Control)
Number of subjects: 60
Study 36285530 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccines, with some patients on preventive antibiotics (n = 6) and/or immunoglobulins replacement therapy (n = 10)
Number of subjects: 118
Study 36285530 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no specific control group mentioned)
Number of subjects: 118
Study 36285536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lufotrelvir (50, 150, 500, or 700 mg continuous 24-hour infusion)
Number of subjects: 15
Study 36285536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lufotrelvir (50-700 mg)
Number of subjects: 15
Study 36285536 — intervention group
Group type: EXPERIMENTAL
Intervention: Lufotrelvir (270 to 350 mg daily continuous infusion)
Number of subjects: 15
Study 36285536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36286004 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride solution applied every 4 weeks
Number of subjects: 148
Study 36286004 — intervention group
Group type: COMPARATOR
Intervention: 5% potassium nitrate solution applied every 4 weeks
Number of subjects: 148
Study 36286755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg 24 hours before CT, 40 mg before CT, and 40 mg after CT (16 patients)
Number of subjects: 100
Study 36286755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg before CT and 40 mg after CT (33 patients)
Number of subjects: 100
Study 36286755 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (52 patients)
Number of subjects: 100
Study 36286862 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 510
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific drug therapy
Number of subjects: 404
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 404
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart failure
Number of subjects: 404
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWD (6-minute walk distance)
Number of subjects: 404
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg dyspnea index
Number of subjects: 404
Study 36286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic parameters
Number of subjects: 404
Study 36286918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of 2 oCDs (Atrial Hypertension and Chronic Heart Failure)
Number of subjects: 5808
Study 36286918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of 3 oCDs (Atrial Hypertension, Coronary Heart Disease, and Chronic Heart Failure)
Number of subjects: 5808
Study 36286918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of 4 oCDs (Atrial Hypertension, Coronary Heart Disease, Chronic Heart Failure, and Diabetes Mellitus)
Number of subjects: 5808
Study 36287047 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive anti-HLA antibodies
Number of subjects: 0
Study 36287047 — intervention group
Group type: COMPARATOR
Intervention: Negative anti-HLA antibodies
Number of subjects: 0
Study 36287231 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus R-CHOP (atezo-R-CHOP)
Number of subjects: 42
Study 36287248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab combined with ibrutinib
Number of subjects: 24
Study 36287523 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention group
Number of subjects: 154
Study 36287523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 36287523 — intervention group
Group type: EXPERIMENTAL
Intervention: Feel4Diabetes intervention
Number of subjects: 154
Study 36287602 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated, interdisciplinary group pulmonary rehabilitation program
Number of subjects: 50
Study 36287929 — intervention group
Group type: EXPERIMENTAL
Intervention: High indoxyl sulfate (IS) levels (cutoff 0.365 mg/dL)
Number of subjects: 150
Study 36287929 — intervention group
Group type: EXPERIMENTAL
Intervention: High myostatin levels (cutoff 4.5 ng/mL)
Number of subjects: 150
Study 36287929 — intervention group
Group type: EXPERIMENTAL
Intervention: Independently associated factors
Number of subjects: 150
Study 36287929 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with glomerular filtration rate (GFR)
Number of subjects: 150
Study 36288197 — intervention group
Group type: EXPERIMENTAL
Intervention: Score-D (scored based on Kinect visualization)
Number of subjects: 20
Study 36288197 — intervention group
Group type: COMPARATOR
Intervention: Score-T (scored by therapist during completion)
Number of subjects: 20
Study 36288238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + Palbociclib
Number of subjects: 10
Study 36288281 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-engineered CAR19 T cells
Number of subjects: 6
Study 36288281 — intervention group
Group type: COMPARATOR
Intervention: Lymphodepletion regimen (fludarabine, cyclophosphamide, and alemtuzumab)
Number of subjects: 6
Study 36288512 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256098
Number of subjects: 36
Study 36288547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily)
Number of subjects: 42
Study 36288547 — intervention group
Group type: EXPERIMENTAL
Intervention: Teliso-V plus erlotinib
Number of subjects: 42
Study 36288619 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMP2-positive patients
Number of subjects: 4
Study 36288619 — intervention group
Group type: COMPARATOR
Intervention: Choroideremia patient
Number of subjects: 4
Study 36288714 — intervention group
Group type: EXPERIMENTAL
Intervention: v-ATPase inhibitors (e.g., etidronate)
Number of subjects: 0
Study 36288714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of etidronate
Number of subjects: 0
Study 36288758 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SAbR) with a median prescribed dose of 45 Gy (range, 35-55) in 5 daily fractions to tumor and 40 Gy (35-45) to nodes.
Number of subjects: 50
Study 36288758 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SAbR)
Number of subjects: 50
Study 36289001 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 725
Study 36289001 — intervention group
Group type: COMPARATOR
Intervention: Non-General Anesthesia (non-GA)
Number of subjects: 725
Study 36289094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg/day plus Pembrolizumab 200 mg every 3 weeks
Number of subjects: 6
Study 36289459 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 190